NanOlogy

NanOlogy Sees ‘Encouraging Signs’ for Its Microparticle Drug Delivery in Nonoperable Lung Cancer Patients

by | Nov 20, 2022

Fort Worth-based NanOlogy has completed the enrollment of 18 patients in a Phase 2a trial for its proprietary particle drug delivery with standard-of care therapy in nonoperable lung cancer patients.

Lung cancer is the most lethal form of cancer with the highest mortality rate, according to the biotech, which aims to improve the treatment of cancer with its tumor-directed technology....

MORE
BionorthTX Names Pharma Entrepreneur, Investor, and Philanthropist as Stone Award Recipient
by | Sep 9, 2019
Among the contributions of recipient Paul Dorman, the chairman and CEO of DFB Pharmaceuticals, is paying for the first-year tuition of the entire inaugural class of M.D. students at the TCU and UNTHSC School of Medicine in Fort Worth.
MORE
Discovery: Blood Plasma and Alzheimer’s, NanOlogy’s Ovarian Cancer Trial & Studying Hurricane Debris
by | Oct 13, 2017
Researchers across North Texas are doing cutting-edge work in a variety of fields — from medicine to weather. Here are some examples.
MORE
nanoparticles
Could NanOlogy’s Nanoparticles Reshape Cancer Treatment?
by | Sep 13, 2017
The technique uses "naked" nanoparticles that can be injected directly into a tumor for greater efficacy and safety.
MORE